Glioblastoma (GBM) is the most aggressive and destructive form of brain cancer. Animal models that can unravel the mechanisms underlying its progression are needed to develop rational and effective molecular therapeutic approaches. In this study, we report the development of mouse models for spontaneous gliomas representing distinct progressive stages of disease that are governed by defined genetic alterations. Neural stem/ progenitor cell (NPC)-specific constitutive Ras activation in vivo plus p53 deficiency led to development of primarily anaplastic astrocytoma (grade III), whereas combined loss of p53 plus p16 Ink4a /p19
Introduction
Glioblastoma (GBM) is the most common high-grade malignant glioma in humans and is categorized as a WHO grade IV glioma, a highly aggressive, invasive, and destructive brain tumor (1) . There are 2 GBM subtypes, primary and secondary, which are distinguished by clinical characteristics. Primary GBM arises de novo in the absence of a preexisting low-grade lesion, whereas secondary GBM develops progressively (over 5-10 years) from lower grade gliomas such as anaplastic astrocytoma (AA, grade III). Alterations in several signaling cascades are known to affect gliomagenesis. These pathways include the receptor tyrosine kinase (RTK)/RAS/ PI3K pathway (including EGFR, PDGFR, NF1, and PTEN); the p53 pathway (including TP53, CDKN2A/p14 ARF , and MDM2); and the RB pathway (including RB1, CDKN2A/p16
INK4A , CDKN2B and CDKN2C; refs. 1, 2).
Several investigators have developed mouse GBM models by genetically engineering glioma mutations. Reilly and colleagues (3) report a mouse model carrying heterozygous cis-germline mutations in the gene encoding a Ras GTPaseactivating protein, Nf1, an effector of RTK signaling, in combination with p53 deficiency. These mice develop malignant gliomas, including GBM and AA, with varying penetrance depending on genetic background (3) . Mouse models harboring a heterozygous germline or conditional somatic p53 mutation combined with conditional somatic Nf1 heterozygosity develop low-to high-grade astrocytomas (4) . Tumor formation is accelerated into high-grade astrocytomas similar to primary GBM by additional loss of Pten (5). Concomitant central nervous system (CNS)-specific deletion of p53 and Pten generates a high-grade malignant glioma phenotype ranging from grade III to grade IV, with notable clinical, pathologic, and molecular resemblance to human malignant gliomas (6) . Furthermore, Alcantara Llaguno and colleagues (7) have shown that inactivation of Nf1 combined with loss of other tumor suppressors (p53 and Pten) in neural stem/progenitor cells (NPC), but not in non-NPCs, was both necessary and sufficient to induce glioma formation, indicating critical roles for Ras activation in NPCs on gliomagenesis in vivo. Thus, these mouse models have provided critical information regarding molecular mechanisms underlying gliomagenesis. However, in these models, phenotypic variations in malignant progression are observed even in the presence of the same mutations (5, 7) . To better understand mechanisms underlying malignant glioma progression, mouse models that reliably control stages of malignant progression are needed.
Although RAS mutations are uncommon in human malignant gliomas, the impact of NF1 inactivation on human and mouse glioma suggested critical roles of RAS activation in gliomagenesis (8) . Proliferation of these tumors requires RAS activation and many of these tumors exhibit elevated RAS signaling, which seems to be central to their pathology (9) . Consistent with this notion, several mouse GBM models have been generated by inducing constitutive Ras activation (10) (11) (12) . In this study, we developed mouse models of gliomagenesis by engineering NPCs to express a constitutively active form of K-Ras via the tamoxifen-induced Cre-loxP system. Interestingly, in combination with loss of the tumor suppressors p53 and p16
Ink4a /p19 Arf , mutant mice developed glioma at 100% penetrance with short latency (within 10 weeks), a clear alteration in malignant progression status. We also observed a correlation between enhanced stem cell properties (stemness) and malignant progression stages, consistent with human samples. Furthermore, we report that Nkx2.2 is a critical factor controlling self-renewal of glioma-initiating cells (GIC), an activity conserved in human GICs. Our mouse brain tumor models could be used to gain important insights into new therapeutic approaches.
Materials and Methods

Mice
LSL-K-Ras
G12D
and p16
Ink4aþ/À /p19
Arfþ/À mice were obtained from the Mouse Models of Human Cancers Consortium of NCI-Frederick (13, 14) . p53 þ/À and Nestin-CreER T2 mice were previously described (15, 16) . Mice were maintained on a mixed 129SvJ/C57BL/6 background. All animal experiments were approved by the Committee on Animal Experimentation of Kanazawa University and performed in compliance with the University's Guidelines for the Care and Use of Laboratory Animals.
Human brain tumor samples
Tumors from patients with glioma were surgically removed and diagnosed at the Department of Neurosurgery, Kanazawa University and at the Department of Neurosurgery, Kumamoto University. All histologic analyses of NKX2.2 expression levels were performed at low-power magnification, and the entire tissue section was evaluated rather than specific foci or selected high-power fields. NKX2.2 expression levels were scored from negative/weak to positive (>30% of tumor cells), depending on the percentage of NKX2.2 þ cells in a given tumor. Human GBM patient-derived GICs, termed TGS-01 and TGS-04, were established as described previously (17) . All human materials and protocols used in this study were approved by ethics committees of Kanazawa University, Kumamoto University, and the University of Tokyo. Informed consent was obtained from all patients.
Tamoxifen induction
To activate CreER T2 in vivo, 1 mg tamoxifen (Sigma) in corn oil (Sigma) was administered intraperitoneally to 8-week-old mice once daily for 5 consecutive days. Immunohistochemistry and immunofluorescence analyses were performed on coronal sections of forebrains obtained at 12 weeks of age.
Tissue preparation and histology
Sacrificed mice were perfused with 4% paraformaldehyde (PFA), and brains were dissected and postfixed overnight in 4% PFA at 4 C. Serial sections were prepared at 5 mm for paraffin sections or 10 mm for cryostat sections. Paraffinembedded mouse brains, mouse gliomas, or human gliomas were deparaffinized and rehydrated prior to immunohistochemical analysis. Tumors were graded according to the WHO grading system for malignant astrocytomas (1).
Antibodies
Immunohistochemistry and immunofluorescence analyses were performed as described (18) . Sections were examined using optical, fluorescence, and confocal microscopy (Keyence BZ-9000, Olympus FV1000, and Carl Zeiss Axio Imager A1 microscopes, respectively). Primary antibodies (Abs) recognizing the following proteins were used for immunostaining assays: Nkx2.2 (Developmental Studies Hybridoma Bank; Sigma), Ki-67 (BD), Nestin (BD and Chemicon), Sox2 (Chemicon), CD133 (eBioscience), GFAP (DAKO), Olig2 (Chemicon), bIII-tubulin (Tuj-1, Covance), NG2 (Chemicon), O4 (Chemicon), cleaved caspase-3 (Cell Signaling), HP1g (Chemicon), g-H2AX (Upstate), phosphoAkt Ser473 (Cell Signaling), CD34 (Chemicon), VEGF (Santa Cruz), PDGFRa (Cell Signaling), myelin basic protein (Mbp; Abcam), and NeuN (Chemicon). Primary Abs were detected using Alexa Fluor-conjugated secondary Abs (Invitrogen), and peroxidase-conjugated secondary Ab (GE Healthcare) plus the DAB Peroxidase Substrate Kit (VECTOR).
Tumor neurospheres
For mouse tumor neurosphere (TNS) formation, mouse glioma cells were isolated from brains of p53 -/-;NR þtamo or
Arf-/-;NR þtamo mice. To assay TNS numbers, dissociated cells (2 Â 10 3 cells/200 mL) were seeded into 96-well plates and cultured for 7 days in medium containing 20 ng/mL fibroblast growth factor-2 (FGF-2; Peprotech) and 20 ng/mL epidermal growth factor (EGF; Peprotech) as described (18) . TNSs derived from TGS-01 and TGS-04 cells were cultured as described (17) . Dissociated cells from sphere preparations were transfected with pLXSBhuman NKX2.2 and cultured as adherent monolayers on poly-L-ornithine-coated coverslips, and then selected in blasticidine-S (8 mg/mL) for 4 days. Transfection was performed using Fugene6 transfection reagent (Roche) according to the manufacturer's instructions. The number of spheres of diameter greater than 50 mm was determined using phase-contrast microscopy. Ink4a-/-/p19 Arf-/-mice were cultured as adherent monolayers with a control GFP shRNA or an Nkx2.2-shRNA-expressing retrovirus suspension, and then selected with puromycin (2 mg/mL) for 4 days, infected with EGFRvIIIexpressing retrovirus (pLERNL), and cultured for an additional 7 days. Levels of Nkx2.2 mRNAs before infection with EGFRvIII-expressing retrovirus were determined by quantitative real-time RT-PCR as described in the following section.
Quantitative RT-PCR
RNAs were purified from cultured NPCs using the RNeasy kit (QIAGEN) and reverse-transcribed using the Advantage RT-for-PCR kit (Takara-Clontech). Real-time quantitative PCR was performed using SYBR green Premix EX Taq (Takara) on an Mx3000P real-time PCR system (Aligent Technology). Sense and antisense primers are listed in Supplementary Table S1 online. The following cycle parameters were used: denaturation at 95 C for 10 seconds, and annealing and elongation for 30 seconds at 57 C for b-actin and at 60 C for Nkx2.2.
Orthotopic transplants
For intracranial injections, TNSs cultured as adherent monolayers were dissociated and resuspended in Hanks Buffered Salt Solution at a concentration of 100,000 viable cells/ mL. Female NOD/SCID mice (Charles River) ages 6 to 8 weeks were anesthetized and placed into a stereotactic apparatus equipped with a z-axis (Stoelting). A small hole was bored into the skull 0.5 mm anterior and 3.0 mm lateral to bregma using a dental drill. Cell suspensions (2 mL) were injected into the right striatum 3 mm below the surface of the brain using a 10 mL Hamilton syringe with a 26 gauge needle. The scalp was closed using an Autoclip Applier. Animals were monitored daily for neurologic deficits.
Western blotting
Western blotting was performed as described (18) . The primary Abs used recognized NKX2.2 (Developmental Studies Hybridoma Bank) or a-tubulin (Sigma).
Statistics
P values were calculated using the unpaired Student's t test. Survival curves were plotted using the Kaplan-Meier method, and differences were analyzed using the log-rank test. The significance of the association between NKX2.2 expression and malignancy was determined by the Fisher's exact test (right tail).
Results
Establishment of mouse glioma models that exhibit malignant progression by in vivo NPC-specific Ras activation
Because Ras signaling is a major pathway upregulated in gliomagenesis, we asked whether Ras activation in NPCs could induce gliomagenesis in vivo. To do so, we established a mouse model in which constitutively activated Ras (K-Ras G12D ) could be specifically and temporally induced in NPCs by binding of tamoxifen to a Cre recombinase-modified estrogen receptor ligand-binding domain fusion protein (Cre-ER T2 ) expressed under control of the Nestin promoter/enhancer (13, 15 Fig. S1 ). Further analysis indicated that both expression of the proliferation marker Ki-67 antigen and 5-bromodeoxyuridine incorporation were reduced in NR þtamo subventricular zone (SVZ) compared with control þtamo SVZ ( Supplementary Fig. S2A-C) . Moreover, immunohistochemical analyses showed no differences between NR þtamo and control þtamo SVZ in numbers of TUNEL þ apoptotic cells ( Supplementary Fig. S3A ) or cleaved caspase-3 þ cells ( Supplementary Fig. S3B ). Although it has been shown that oncogenic signaling induces cellular senescence in vitro and in vivo, we observed no significant differences between control þtamo and NR þtamo SVZ cells in expression of the senescence-associated markers HP1g or g-H2AX ( Supplementary Fig. S3C 
/p19
ArfÀ/À mice and infected with retrovirus carrying K-Ras G12V develop GBMs (10, 21) . It was reported that GBM also arises when p16
Ink4aÀ/À or p19
ArfÀ/À mice are engineered to overexpress mutant K-Ras gene in vivo (10) . By contrast to those studies, in our model the mutant K-Ras allele is expressed at physiologic levels. Therefore, discrepancies are likely due to differences in the amplitude of oncogenic signaling, the age of the mice used, or the cellular context (transformation in vitro or in vivo).
To investigate the effect of loss of multiple tumor suppressors in our model, we crossed NR mice with p53 and p16 Ink4a / p19
Arf mutant mice. Simultaneous deletion of p16 Ink4a /p19
Arf plus p53 significantly shortened the survival time of NR þtamo mice (Fig. 1A) . Interestingly, in contrast with p53 À/À ;NR þtamo mice, histologic analyses revealed that 100% of the tumors in p53
;p16 Ink4a-/-/p19 ArfÀ/À ;NR þtamo mice were GBMs (Fig. 1D) . As shown in Figure 2A and C, GBMs derived from p53 À/À ;p16 growth factor (Vegf) and phosphorylated Akt (p-Akt). Coactivation of multiple RTKs, which is often seen in human primary GBMs, was also evident in our murine GBMs, in which we observed markedly upregulated Pdgfra expression. By contrast, AA seen in p53
;NR þtamo mice showed only low levels of Ki-67, Nestin, VEGF, p-Akt, and Pdgfra ( Fig. 2A and  C) . Microvascular formation in mouse GBMs was confirmed by detection of the endothelial marker CD34 (Fig. 2A) .
Enhanced stem cell properties (stemness) accompanies malignant progression in mouse glioma models Previous reports of human GBMs indicate that several stem cell markers, including Nestin, Sox2, and CD133 are upregulated in these malignancies (22) (23) (24) . Likewise, we found that Nestin, Sox2, and CD133 were upregulated in GBMs from p53 À/À ;p16 Fig. S5 ). Expression of Mbp or O4, both of which are expressed in mature oligodendrocytes, was not observed in either type of glioma (Supplementary Fig. S5 and data not shown) . However, interestingly, Nkx2.2, a homeodomain transcription factor essential for oligodendroglial differentiation, was strongly expressed in AAs but barely detectable in GBMs (Fig. 2D) . These data suggest that mechanisms governing oligodendroglial differentiation may play a critical role in regulating malignant progression of glioma.
Nkx2.2 regulates mouse gliomagenesis
Our observation that malignant glioma progression is inversely correlated with loss of Nkx2.2 expression suggested that presence of Nkx2.2 inhibits GBM formation. To test this hypothesis, we assessed the effects of Nkx2.2 upregulation on the fate of GICs within TNSs derived from GBMs. Nkx2.2 reportedly induces oligodendroglial differentiation of normal NPCs (25, 26) . We overexpressed Nkx2.2 in dissociated GBM cells derived from p53
Ink4a-/-/p19
IArf-/-;NR þtamo mice and examined TNS formation. Nkx2.2 overexpression markedly reduced both the numbers of TNSs formed and their expression of Nestin ( Fig. 3A and B) . Notably, cells within these TNSs showed increased expression of the oligodendrocyte markers, chondroitin sulfate proteoglycan (NG2), O4, and Mbp. These data indicate that Nkx2.2 can induce oligodendroglial differentiation of GICs, decreasing their self-renewal capacity (Fig. 3B ). Next we used intracranial injection to introduce vector-transduced murine TNSs into NOD/SCID mice (n ¼ 10), lethal, infiltrating gliomas developed in brains of all mice within 1 month. By contrast, all mice (10 of 10) injected with TNSs overexpressing Nkx2.2 survived for more than 2 months (Fig. 3C) . Thus, induction of oligodendroglial differentiation of GICs by Nkx2.2 suppresses GBM formation in vitro.
To directly examine the effect of Nkx2.2 loss on gliomagenesis, we assessed the ability of NPCs in which Nkx2.2 was downregulated via shRNA knockdown to promote gliomagenesis in a different genetic murine glioma model, the EGFRvIIIinduced GBM model (27) . Introduction of Nkx2.2 shRNA into cultured NPCs from these mice efficiently knocked down Nkx2.2 expression (Fig. 3D) . When recipient mice were inoculated with p16
Ink4a-/-/p19 Arf-/-NPCs expressing EGFRvIII plus Nkx2.2 shRNA, mouse survival was significantly shorter than that of recipients that received p16
ArfÀ/À NPCs expressing EGFRvIII plus control shRNA (Fig. 3D ). Histologic differences were not observed between gliomas arising from NPCs transduced with control versus Nkx2.2 shRNAs (data not shown). These data suggest that Nkx2.2 downregulation accelerates formation of lethal GBMs.
NKX2.2 suppresses self-renewal of human GICs by induction of oligodendroglial differentiation in vitro
To investigate whether our findings are relevant to human gliomas, we first examined NKX2.2 protein expression in 96 human high-grade gliomas: 33 GBMs, 36 AAs, and 27 anaplastic oligodendrogliomas (AO). As previously reported, immunohistochemical analysis revealed that NKX2.2 was expressed at higher levels in AOs (22 positive cases in 27 AOs, 81%) than the levels in AAs (15 positive cases in 36 AAs, 42%; Fig. 4) . Interestingly, most GBMs (28 cases in 33 GBMs) did not express NKX2.2 (Fig. 4) . Thus, in both humans and mice, NKX2.2 suppression is positively correlated with increased malignancy in astrocytomas.
To assess the relevance of our findings to human GICs, we examined the effect of NKX2.2 overexpression on TNS formation by GICs. To do so, we used early passage, patient-derived GIC lines, termed TGS-01 and TGS-04, which under serum-free conditions retain phenotypes and genotypes more closely mirroring primary tumor profiles (17) . NKX2.2 overexpression markedly reduced both the number of TNS formed from GICs and their expression of Nestin (Fig. 5A-D) . In addition, cells within these TNSs showed increased O4 expression. These data indicate that NKX2.2 can decrease self-renewal capacity and induce oligodendroglial differentiation of human GICs in vitro, suggesting that mechanisms observed in our mouse models are conserved in human GICs. To examine whether NKX2.2 is directly regulated by transforming growth factor b (TGFb) or bone morphogenetic protein 4 (BMP) signal, which is involved in maintenance of GICs (17, 28, 29) , we examined the effects of the TGFb inhibitor (SB431542, 1 mmol/L) and BMP4 (100 nmol/ L) on NKX2.2 expression in TGS-01 by immunoblotting and immunocytochemistry. NKX2.2 expression was not remarkably affected by these treatments (data not shown) nor was phosphorylation of Smad2/3 and Smad1/5/8 altered by NKX2.2 overexpression. These data suggest that NKX2.2 does not directly interact with TGFb or BMP signaling in human GICs. 
/p19
Arf-/À mice were cultured, infected with EGFRvIII-expressing virus, cultured for 7 more days, and injected into brains of NOD/SCID mice. Kaplan-Meier tumor-free survival curves are shown.
Discussion
Here, we have established mouse models harboring specific mutations that allow us to control stages of malignant glioma progression (AA versus GBM). These models provide significant advantages in comparing characteristics of gliomas of different malignant progression stages. Mutations seen in human cancers may differ from those seen in mouse models. Nonetheless, mouse models are essential and indispensable to fully understand the nature of gliomas. Our models represent powerful tools useful to identify novel factors that control glioma malignant progression.
A stem cell-like gene expression signature (stemness) has been shown in poorly differentiated tumors, based on histologic criteria. Stemness is associated with an unfavorable prognosis in several human cancers, including gliomas (30) . Consistent with these data, we observed enhanced stemness characteristics, including upregulation of stem cell markers or sphere formation, in GBM (grade IV) tumors but not AA (grade III) in our mouse models. Although the mechanism is still unclear, several lines of evidence show that genetic loss of p53 or p16 Ink4a /p19 Arf enhances stemness. For example, p53 or p16 Ink4a /p19
Arf deficiency increases both the kinetics of induced pluripotent stem (iPS) cell reprogramming and the number of emerging iPS cell colonies (31) (32) (33) (34) (35) Arf have a central role in limiting expansion of multipotent progenitors. Because differentiation pathways are commonly repressed in tumor cells, the above results plus our findings suggest a mechanism by which incipient neoplastic cells could gain the ability to self-renew, acquire further oncogenic mutations, and become malignant.
Our study reveals a critical role for Nkx2.2 in suppressing glioma development and GIC self-renewal. A direct effect of Nkx2.2 on oligodendroglial differentiation is supported by previous analyses of mouse spinal cord (25) . Coexpression of Olig2 and Nkx2.2 in spinal cord (26) SVZ of the midbrain promotes oligodendrocyte differentiation (37) . Olig2 is essential for proliferation and differentiation of oligodendrocyte precursors (38, 39) . Olig2-expressing precursors give rise not only to oligodendrocytes but to motor neurons (26, 40) , astrocytes, and ependymal cells (41, 42) . In contrast to Olig2, Nkx2.2 generally regulates late differentiation and/or maturation, rather than initial specification, of oligodendrocyte precursors (25) , although Nkx2.2 does support generation of new oligodendrocytes or remyelination in adults with CNS injury (43, 44) . Nkx2.2 cooperates with Olig2 to promote oligodendrocyte maturation to Mbp-positive stages (26, 45) . Although several lines of evidence suggest that Olig2 activity represents a mechanistic link between growth of malignant glioma cells and adult NPCs (46, 47) , data regarding the role of Nkx2.2 role in gliomagenesis are not available. Our findings suggest that Nkx2.2 functions as a cell fate switch determining whether NPCs receiving oncogenic stimulation develop into benign glial cells or malignant astrocytomas.
Rousseau and colleagues (48) previously reported that NKX2.2 was expressed at higher levels in human AO than in AA and GBMs, suggesting that NKX2.2 is a marker that distinguishes AO from astrocytomas. In addition, it has been reported that NKX2.2 expression is elevated in a proneural subgroup of human GBM (49) . In our examination of a larger group of clinically defined samples, we found that NKX2.2 is not only a marker for AO but also an indicator of malignant progression in astrocytomas, suggesting that NKX2.2 expression antagonizes malignant progression of most gliomas. In addition, we showed that impaired oligodendroglial differentiation caused by Nkx2.2 downregulation accelerates GBM formation in a robust murine model of primary gliomagenesis. Our work shows that Nkx2.2 antagonizes glioma initiation and malignant progression induced by activation of oncogenic signaling in NPCs. Finally, we show that forced Nkx2.2 expression in GICs leads to oligodendroglial differentiation and suppression of self-renewal in vitro. However, it is unclear whether the inhibitory effects of NKX2.2 on glioma malignancy in vivo are mediated by the process of oligodendroglial differentiation, because in both mouse and human samples the mature oligodendrocyte marker, MBP, is not expressed in AA. NKX2.2 may affect malignant progression by an unknown function in vivo. Nonetheless, reactivation of NKX2.2 expression in glioma cells suggests a novel therapeutic strategy. In summary, our novel mouse glioma models allow us to analyze two grades of glioma rapidly and define molecular mechanisms underlying malignant glioma progression. Thus, understanding signaling driving malignant gliomagenesis in our models could contribute to development of novel approaches to diagnose and/or eradicate cancer.
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